15-min delayed · Sep 4, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Larimar Therapeutics Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $5.00 to $21.00 (about 4.2x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $11.67 sits 205% above the current $3.82. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.38 next quarter toward $-1.06 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Larimar Therapeutics Inc.
As of Sep, 6 of 6 firms rate LRMR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
LRMR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.38
Range $-0.45 – $-0.34 · 7 analysts · -47% YoY
Next period, 7 analysts expect Larimar Therapeutics Inc to earn $-0.38 a share (range $-0.45 – $-0.34), versus $-0.73 a year earlier. Full-year consensus is $-1.35, growing to $-1.06 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $41.7M next year.
Top analysts covering Larimar Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LRMR.
#1
Yatin Suneja
Guggenheim · Rank #21
Buy
$26.00+580.6% to target
Overall win rate
53%
+ Follow
#2
Jonathan Wolleben
JMP Securities · Rank #29
Buy
$18.00+371.2% to target
Overall win rate
47%
+ Follow
#3
Laura Chico
Wedbush · Rank #74
Buy
$11.00+188.0% to target
Overall win rate
44%
+ Follow
#4
Joel Beatty
Baird · Rank #80
Buy
$5.00+30.9% to target
Overall win rate
48%
+ Follow
#5
Andreas Argyrides
Oppenheimer · Rank #242
Buy
$21.00+449.7% to target
Overall win rate
45%
+ Follow
LRMR stock forecast FAQ
What is LRMR's average 12-month price target?+
The 6 analysts with a live target average $11.67 for Larimar Therapeutics Inc over the next 12 months, ranging from a $21.00 high to a $5.00 low.
Is LRMR stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for LRMR?+
The Street-high target is $21.00 (Oppenheimer), and the Street-low is $5.00 (Baird). The average of all 6 active targets is $11.67.
How many Wall Street analysts cover LRMR?+
6 analysts have an active rating on Larimar Therapeutics Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering LRMR?+
Among analysts who currently cover LRMR, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #21). Their current call is Buy with a $26.00 target.
What is Larimar Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.38 per share (range $-0.45 – $-0.34) across 7 analysts. Full-year EPS is projected at $-1.35, rising to $-1.06 the following year.
How much revenue is Larimar Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $41.7M next year.
Have analysts been upgrading or downgrading LRMR lately?+
As of Sep, 6 of 6 firms rate LRMR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LRMR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
